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Background: In chronic obstructive pulmonary disease (COPD), the blood vitamin D3 level is 
generally low, and genetic polymorphisms of vitamin D-binding protein encoded by the GC gene 
are associated with COPD development. In this study, we examined the relationship between 
GC polymorphisms and plasma vitamin D3 level in Korean patients with COPD.
Methods: The study included 175 COPD patients from the Korean Obstructive Lung Disease 
Cohort. Multivariate analysis was conducted with adjustment for age, body mass index (BMI), 
lung function, smoking status, smoking amount, and seasonal variation in blood vitamin D level. 
Vitamin D deficiency was defined as a plasma 25-hydroxyvitamin D
3
 level lower than 20 ng/mL.
Results: The mean plasma vitamin D3 level was 17.5 ng/mL. The GC1F variant (44.3%) and 
genotype 1F-2 (27.4%) were the most common. The plasma vitamin D3 level was lower in 
patients with the GC2 variant (estimated =-3.73 ng/mL) and higher in those with genotype 1F-1S 
(estimated =4.08 ng/mL). The GC2 variant was a significant risk factor for vitamin D deficiency 
(odds ratio =2.41). Among COPD clinical parameters, vitamin D deficiency was associated 
with a lower ratio of forced expiratory volume in 1 second to forced vital capacity (FEV
1
/
FVC) regardless of GC polymorphisms. FEV
1
/FVC was higher in patients with genotype 1F-1F 
(estimated =3.61%) and lower in those with genotype 1F-2 (estimated =-3.31%). The 6-minute 
walking distance was shorter for patients with the GC1F variant (estimated =-38.91 m) and 
longer for those with the GC2 variant (estimated =26.98 m). The emphysema index was higher 
for patients with the GC1S variant (estimated =6.56%) and genotype 1F-1S (estimated =9.86%), 
regardless of the vitamin D level.
Conclusion: The GC2 variant is a risk factor for vitamin D deficiency, and genotype 1F-1S is 
a protective factor against vitamin D deficiency. GC polymorphisms and vitamin D deficiency 
correlate with clinical outcomes for Korean patients with COPD.
Keywords: vitamin D-binding protein, polymorphism, vitamin D, chronic obstructive 
pulmonary disease
Introduction
Chronic obstructive pulmonary disease (COPD) has been recognized as a systemic 
disease associated with various comorbidities.1 Accumulating evidences demonstrate 
high prevalence of low vitamin D status in chronic illnesses, such as cancers, autoim-
mune diseases, infectious and cardiovascular diseases, and also in COPD.2–4 Although 
previous studies have examined the effects of vitamin D3 level or vitamin D deficiency 
on various clinical characteristics of COPD, the results are conflicting.5–8
Vitamin D-binding protein (VDBP) is a serum protein encoded by the GC gene 
located on chromosome 4q13. It was first described by J Hirschfeld in 1959 as a marker 
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for gamma globulin in human serum.9 VDBP is the main 
carrier protein of 25-hydroxyvitamin D, the major circulating 
form of vitamin D, and 1,25-dihydroxyvitamin D, the most 
active vitamin D metabolite. Neutrophil-expressed VDBP 
activates macrophages and augments monocyte and neutrophil 
chemotaxis,10–13 which may contribute to chronic inflammatory 
response observed in COPD. Among more than 120 types of 
GC genetic variants, single-nucleotide polymorphisms rs4588 
and rs7041 at codons 416 and 420 in exon 11 are the most 
common, resulting in three functional variants: GC1F(A/G), 
GC1S(A/T), and GC2(C/G), which give rise to six genotypes 
(GC1F-1F, GC1F-1S, GC1F-2, GC1S-1S, GC1S-2, and 
GC2-2).14 The association of GC polymorphisms with suscep-
tibility of COPD has been explored in several studies.15–18
Although vitamin D status and GC polymorphisms are 
closely related, their association with clinical outcomes 
in COPD has not been yet investigated, since most of the 
previous studies on COPD have examined the individual 
contribution of each factor.6,16,17 Therefore, the purpose of 
this study was to determine the relationship between common 
GC polymorphisms and vitamin D3 level in Korean patients 
with COPD. We assumed that certain GC variants would be 
associated with vitamin D3 level, indicating susceptibility to 
vitamin D deficiency. Moreover, we aimed to evaluate the 
relative contribution of GC polymorphisms and vitamin D 
status to various clinical outcomes in patients with COPD.
Materials and methods
study subjects
The study population consisted of 175 patients from the 
Korean Obstructive Lung Disease (KOLD) Cohort, which 
comprises patients with COPD or asthma treated in pulmo-
nary clinics of 17 hospitals in South Korea from June 2005 
to December 2011. The inclusion criteria were as follows: 
post-bronchodilator ratio of forced expiratory volume in 
1 second to forced vital capacity (FEV
1
/FVC) ,0.7, age over 
40 years, smoking history of ten or more pack-years, and 
no or minimal abnormality detected by chest radiography. 
The study protocol was approved by the institutional review 
boards of the 17 hospitals included in the KOLD Cohort 
(Asan Medical Center, Hanyang University Guri Hospital, 
Inje University Ilsan Paik Hospital, Bundangcha Hospital, 
Kangbook Samsung Medical Center, Ewha Womans Uni-
versity Mokdong Hospital, Kangwon National University 
Hospital, Korea University Anam Hospital, Seoul National 
University Hospital, Seoul National University Bundang Hos-
pital, Hallym University Medical Center, Konkuk University 
Medical Center, Ajou University Hospital, National Medical 
Center, The Catholic University of Korea Seoul St Mary’s 
Hospital, The Catholic University of Korea Yeouido St 
Mary’s Hospital, Severance Hospital), and informed written 
consent was obtained from all the patients.
Blood collection and measurement of 
plasma vitamin D3 level
Plasma samples were assayed for 25-hydroxyvitamin D
3
 
using a radioimmunoassay kit (DiaSorin, Stillwater, MN, 
USA), and vitamin D deficiency was defined as plasma levels 
of 25-hydroxyvitamin D
3
 lower than 20 ng/mL.19
COPD clinical parameters
COPD status was assessed according to four parameters: 
pulmonary function, 6-minute walking (6MW) distance, 
quality of life evaluated by St George’s Respiratory Ques-
tionnaire (SGRQ), and emphysema index.
genotyping
DNA was extracted from blood for GC genotyping. The 
region that included two-point mutation at codons 416 
and 420 in exon 11 (causing Glu416/Asp and Thr420/
Lys substitutions) was amplified by polymerase chain 
reaction (PCR) using the following primers: upstream, 
5′-TAATGAGCAAATGAAAGAAG-3′ and downstream, 
5′-TGAGTAGATTGGAGTGCATAC-3′ to obtain a 462 
bp product. PCR was performed in a DNA Thermal Cycler 
(PerkinElmer Inc., Waltham, MA, USA) in a reaction volume 
of 40 μL containing 100 ng DNA, 1.5 mM MgCl
2
, 10 mM 
Tris Cl (pH 8.3), 40 mM KCl, 4% dimethyl sulfoxide, 0.2 mL 
of each deoxynucleoside triphosphate (dNTP) (Amersham 
Biosciences KK, Tokyo, Japan), 0.5 μM of each primer, and 
3.75 units of Taq DNA polymerase (Bioneer, Daejeon, Korea). 
After amplification, restriction fragment-length polymorphism 
analysis was performed by digesting PCR products with 
HaeIII (Toyobo, Osaka, Japan) or EcoT14 I (Takara Bio, Otsu, 
Japan) at 37°C overnight. GC1S was cut by HaeIII into 295 
and 167 bp fragments and by EcoT14 I into 302 and 156 bp 
fragments, while GC1F was not cut by either enzyme.
Computed tomography data acquisition 
and analysis
Volumetric computed tomography (CT) scans were per-
formed at full inspiration and expiration using a 16-multiple 
detector CT scanner (Somatom Sensation; Siemens 
Medical Systems, Erlangen, Germany). The images were 
reconstructed using the soft kernel B30f (Siemens Medical 
Systems) from the thoracic inlet to the lung base. Images 
of the entire lungs were automatically extracted using the 
in-house software, and the attenuation coefficient of each 
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pixel was measured and calculated. The cutoff level between 
normal lung density and low-attenuation area was defined 
as -950 HU. Quantitative assessment of emphysema was 
expressed as the percent of low attenuation.20
statistical analysis
Categorical variables were analyzed using chi-square test 
or Fisher’s exact test, and continuous variables were ana-
lyzed using Student’s t-test or the Mann–Whitney U-test. 
Normally distributed variables were presented as mean 
± standard deviation, and non-normally distributed vari-
ables were presented as median values and interquartile 
range. Multiple linear regression analysis was conducted to 
investigate the effects of GC variants/genotypes on vitamin 
D3 level, and to evaluate the relationship of GC variant/
genotypes and vitamin D deficiency with various clinical 
parameters in COPD. Statistical adjustment was performed 
for lung function, age, body mass index (BMI), smoking 
status (current/former), smoking amount (pack-years), and 
seasonal variation in plasma vitamin D3 level. Logistic linear 
regression analysis was conducted to determine significant 
GC variants/genotypes for vitamin D deficiency. In all 
analyses, a P-value ,0.05 was considered to be statistically 
significant.
Results
Patients’ characteristics
Baseline characteristics of the study population are sum-
marized in Table 1. Mean age was 66.4 years with male 
dominance (97.7%). Disease staging was performed accord-
ing to the previous Global Initiative for Chronic Obstructive 
Lung Disease (GOLD): 12 (6.9%), 87 (49.7%), 64 (36.6%), 
and 12 (6.9%) patients were categorized into stages I, II, III, 
and IV, respectively. The GC1F variant (44.3%) and geno-
type 1F-2 (27.4%) were the most common. The mean 
plasma level of vitamin D3 was 17.5 ng/mL with seasonal 
variations; it was higher in summer (June–August) and fall 
(September–November) than in spring (March–May) and 
winter (December–February) (Table 2).
association of vitamin D3 level with gC 
variants and genotypes
Vitamin D3 plasma levels and vitamin D deficiency distri-
bution were compared between different GC variants and 
genotypes (Table 3). Patients with the GC2 variant had 
lower plasma vitamin D3 levels than non-GC2 patients 
(15.5 vs 19.9 ng/mL, P=0.002) and higher proportion of 
vitamin D deficiency (78.9% vs 58.8%, P=0.004). Patients 
with genotype 1F-1S had higher plasma levels of vitamin D3 
Table 1 Baseline characteristics of the study population
Characteristics Total participants 
(N=175)*
sex, male 171 (97.7)
age, years 66.4±6.8
height, cm 165.4±6.2
BMI, kg/m2 22.9±3.4
smoking status
Current 45 (25.7)
Former 130 (74.3)
Pack-years 45.6±23.1
Underlying diseases
Coronary vascular disease 18 (10.3)
Cerebrovascular disease 7 (4.0)
hypertension 55 (31.4)
Diabetes mellitus 19 (10.9)
Chronic kidney disease 3 (1.7)
liver disease 7 (4.0)
asthma 50 (28.6)
Malignancy 6 (5.1)
FeV1, l 1.51±0.51
FeV1, % predicted 57.5±18.0
FVC, l 3.16±0.84
FVC, % predicted 84.1±20.9
FeV1/FVC, % 48.0±10.6
GOLD classification
I 12 (6.9)
II 87 (49.7)
III 64 (36.6)
IV 12 (6.9)
Measured with emphysema index, % (n=131) 21.9±16.5
Measured with 6MW distance,  
meters (m) (n=129)
438.7±77.5
Plasma 25-hydroxyvitamin D3 level, ng/ml 17.5±9.5
VDBP variants (n=350)#
GC1F 155 (44.3)
GC1S 83 (23.7)
GC2 112 (32.0)
genotypes (n=175)
1F-1F 35 (20.0)
1F-1s 37 (21.1)
1F-2 48 (27.4)
1s-1s 8 (4.6)
1s-2 30 (17.1)
2-2 17 (9.7)
Note: *Data are presented as the number of patients (percentage) or mean ± 
standard deviation. #number of total variants; because there are two variants in 
each individual, double the number (350) of 175 is included in the analysis.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; gOlD, global Initiative for Chronic Obstructive lung 
Disease; 6MW, 6-minute walking; VDBP, vitamin D-binding protein.
Table 2 seasonal variation in baseline plasma vitamin D level
Season Participants 
(N)
Mean ± SD,  
ng/mL
P-value
spring (March–May) 29 14.6±9.1
0.013*
summer (June–august) 77 19.1±8.1
autumn (september–november) 46 18.8±12.2
Winter (December–February) 23 13.2±5.3
Note: *One-way analysis of variance was used.
Abbreviation: sD, standard deviation.
}
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Table 3 Plasma vitamin D level according to GC variants and 
genotypes
Variables Participants  
(N)
Vitamin D  
level, ng/mL*
Vitamin D 
deficiency#
Variant
GC1F 120 18.3±9.6 79 (65.8)
non-GC1F 55 15.7±9.0 43 (78.2)
P-value 0.094 0.099
GC1S 75 18.3±10.7 52 (69.3)
non-GC1S 100 16.9±8.5 70 (70.0)
P-value 0.328 0.924
GC2 95 15.5±8.8 75 (78.9)
non-GC2 80 19.9±9.7 47 (58.8)
P-value 0.002 0.004
Genotype
1F-1F 35 18.5±7.0 20 (57.1)
non-1F-1F 140 17.3±10.0 102 (72.9)
P-value 0.500 0.070
1F-1s 37 20.7±11.4 23 (62.2)
non-1F-1s 138 16.7±8.8 99 (71.7)
P-value 0.021 0.260
1F-2 48 16.4±9.5 36 (75.0)
non-1F-2 127 17.9±9.5 86 (67.7)
P-value 0.336 0.350
1s-1s 8 22.2 (11.7–33.6) 4 (50.0)
non-1s-1s 167 15.5 (10.9–22.0) 118 (70.7)
P-value 0.189 0.246
1s-2 30 14.2±8.1 25 (83.3)
non-1s-2 145 18.2±9.6 97 (66.9)
P-value 0.034 0.075
2-2 17 15.0 (8.1–19.9) 14 (82.4)
non-2-2 158 15.8 (11.3–22.8) 108 (68.4)
P-value 0.164 0.233
Notes: *Data are presented as mean ± standard deviation, median (interquartile 
range) or P-value. #Data are presented as the number of patients (percentage) or 
P-value. Vitamin D deficiency was defined as plasma level of 25-hydroxyvitamin D3 
lower than 20 ng/ml.
Table 4 adjusted estimates of various factors for plasma vitamin D level
Model 1: variant GC2 Model 2: genotype 1F-1S
Estimated Standard error P-value Estimated Standard error P-value
Variant/genotype -3.73 1.44 0.010 4.08 1.73 0.020
age, years 0.06 0.11 0.589 0.07 0.11 0.525
BMI, kg/m2 -0.07 0.23 0.781 -0.09 0.23 0.687
FeV1, % predicted -0.04 0.05 0.463 -0.04 0.05 0.403
FeV1/FVC 0.20 0.09 0.029 0.25 0.09 0.005
smoking status -2.71 1.64 0.099 -2.39 1.65 0.149
smoking, pack-years 0.05 0.03 0.096 0.06 0.03 0.061
seasonal variation in plasma vitamin D level 0.10 0.78 0.901 0.04 0.79 0.957
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
than non-1F-1S individuals (20.7 vs 16.7 ng/mL, P=0.021), 
while those with genotype 1S-2 had lower plasma levels 
of vitamin D3 than non-1S-2 patients (14.2 vs 18.2 ng/mL, 
P=0.034). There was no difference in the distribution of 
vitamin D deficiency among different genotypes.
effects of gC variants/genotypes on 
plasma vitamin D3 level
Multiple linear regression analysis of the association between 
GC variants/genotypes and plasma vitamin D3 levels indicated 
that plasma vitamin D3 levels were lower in patients carry-
ing the GC2 variant (estimated =-3.73 ng/mL, P=0.010) and 
higher in those with genotype 1F-1S (estimated =4.08 ng/mL, 
P=0.020) (Table 4). Logistic regression analysis indicated 
that the GC2 variant was a significant risk factor for 
vitamin D deficiency (odds ratio =2.41, 95% confidence 
interval: 1.19–4.92, P=0.015) (Figure 1).
effects of gC variants/genotypes and  
vitamin D deficiency on clinical 
parameters of COPD
The effects of GC variants/genotypes and plasma vitamin D3 
level on COPD clinical parameters (FEV
1
, FEV
1
/FVC, 
6MW distance, SGRQ score, and emphysema index) were 
evaluated after adjusting for lung function, age, BMI, 
smoking status (former/current), smoking amount (pack-
years), and seasonal variation in plasma vitamin D3 level 
(Table 5). Nine different models were analyzed with three 
variants and six genotypes. FEV
1
 and SGRQ score were 
not influenced by either GC variants/genotypes or vitamin 
D deficiency. Patients with vitamin D deficiency showed 
lower FEV
1
/FVC regardless of GC polymorphism. Patients 
with the GC2 variant (estimated =-2.46%, P=0.050) or 
genotype 1F-2 (estimated =-3.31%, P=0.015) showed 
lower FEV
1
/FVC compared to those without these poly-
morphisms, while those with genotype 1F-1F (estimated = 
3.61%, P=0.018) showed higher FEV
1
/FVC. After adjust-
ment, vitamin D deficiency was found to be associated 
with shorter 6MW distance for the GC1F and GC2 vari-
ants and genotypes 1F-1F, 1F-1S, and 2-2 (Table 5). The 
GC1F (estimated =-38.91%, P=0.009) and GC2 variants 
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Table 5 Adjusted estimates of VDBP variants/genotypes and vitamin D deficiency* for FEV1/FVC, 6MW distance, and emphysema 
index
Models FEV1/FVC
# 6MW distance† Emphysema index^
Estimated SE P-value Estimated SE P-value Estimated SE P-value
Model 1
Variant GC1F -1.35 1.33 0.309 -38.91 14.54 0.009 – – –
Vitamin D deficiency -3.39 1.34 0.013 -33.57 15.17 0.029
Model 2
Variant GC1S -0.75 1.24 0.547 – – – 6.56 2.85 0.023
Vitamin D deficiency -3.26 1.34 0.016 1.78 3.37 0.599
Model 3
Variant GC2 -2.46 1.25 0.050 26.98 12.83 0.038 – – –
Vitamin D deficiency -2.67 1.36 0.051 -35.46 15.60 0.025
Model 4
genotype 1F-1F 3.61 1.52 0.018 -19.42 16.57 0.244 – – –
Vitamin D deficiency -2.85 1.33 0.034 -31.47 15.68 0.048
Model 5
genotype 1F-1s -1.20 1.51 0.428 -24.60 15.01 0.105 9.86 3.20 0.003
Vitamin D deficiency -3.34 1.34 0.014 -31.05 15.48 0.048 2.10 3.31 0.528
Model 6
genotype 1F-2 -3.31 1.35 0.015 – – – – – –
Vitamin D deficiency -2.97 1.32 0.026
Model 7
genotype 1s-1s 4.66 2.90 0.110 – – – -13.11 6.00 0.031
Vitamin D deficiency -3.05 1.34 0.023 0.90 3.38 0.790
Model 8
genotype 1s-2 -1.35 1.63 0.408 – – – – – –
Vitamin D deficiency -3.11 1.35 0.022
Model 9
genotype 2-2 3.13 2.06 0.131 41.84 24.23 0.088 – – –
Vitamin D deficiency -3.41 1.34 0.012 -33.71 15.65 0.034
Notes: *Vitamin D deficiency was defined as plasma level of 25-hydroxyvitamin D3 lower than 20 ng/ml. 
#adjusted for age, BMI, smoking status (former or current smoker), 
pack-years, seasonal variation in plasma vitamin D level, and FeV1 % predicted (n=174). †adjusted for age, BMI, smoking status (former or current smoker), pack-years, 
seasonal variation in plasma vitamin D level, FeV1 % predicted, and FeV1/FVC (n=129). ^adjusted for age, BMI, smoking status (former or current smoker), pack-years, 
seasonal variation in plasma vitamin D level, FeV1 % predicted, and FeV1/FVC (n=131). ‘–’ represents data that were statistically not significant.
Abbreviations: VDBP, vitamin D-binding protein; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 6MW, 6-minute walking; se, standard error; BMI, 
body mass index.
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Figure 1 Risk of vitamin D deficiency in COPD patients with various GC polymorphisms.
Notes: (A) Three different variants; (B) six different genotypes. Data are presented as odds ratio and 95% confidence interval for each GC variant and genotype.
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(estimated =26.98%, P=0.038) showed shorter and longer 
6MW distances, respectively. For the emphysema index, 
the GC1S variant (estimated =6.56%, P=0.023) and geno-
type 1F-1S (estimated =9.86%, P=0.003) correlated with 
higher emphysema index values and genotype 1S-1S 
(estimated =-13.11%, P=0.031) with lower emphysema 
index compared to COPD patients without these genetic 
variations. However, no association was observed between 
the emphysema index and vitamin D deficiency.
Discussion
This study investigated the association between GC poly-
morphisms and vitamin D deficiency in Korean patients 
with COPD. Genotype 1F-1S was related with higher 
vitamin D levels, while the GC2 variant correlated with lower 
vitamin D3 levels; the latter showed a significant association 
with vitamin D deficiency. Moreover, in Korean patients with 
COPD, GC polymorphisms and vitamin D deficiency affected 
several clinical parameters of the disease, including FEV
1
/
FVC, 6MW distance, and emphysema index.
Previous studies have investigated the association 
between GC polymorphisms and susceptibility to COPD.13,16 
Thus, a meta-analysis study has revealed that in Asian popu-
lation, genotype 1F-1F is a risk factor for developing COPD, 
while genotype 2-2 indicates protection against the disease. 
In Korean population, genotype 1S-1S has been identified as 
a risk factor for COPD.17 However, no significant associa-
tion has been found between GC polymorphisms and COPD 
susceptibility in Caucasian population.16
Although a number of genome-wide association studies 
have analyzed the relationship between GC polymorphisms 
and vitamin D status, pathophysiology of how GC poly-
morphism affects vitamin D status is not clear.21–26 The 
GC1F and GC1S genotypes carry a single polymorphism 
at position 416 (Glu/Asp), while GC1F and GC2 carry a 
substitution at position 420 (Thr/Lys). Thus, the GC1S and 
GC2 genotypes encode proteins differing by two amino acids 
at positions 416 and 420, which accounts for the difference 
in isoelectric points27,28 and binding affinity to vitamin D3.29 
Cohort and genome-wide association studies have revealed 
that GC polymorphisms are strong determinants of circulat-
ing vitamin D3 levels, which, however, may depend on ethnic 
background.21–26 Thus, the GC2 variant was associated with 
lower vitamin D3 levels in healthy young Canadian adults 
of East Asian and European ancestry, but not of South Asian 
ancestry.21 In this study, we found that the plasma vitamin D3 
level and distribution of vitamin D deficiency were associated 
with GC polymorphisms in Korean patients with COPD.
The major function of VDBP is binding, solubilization, 
and transportation of vitamin D and its metabolites.27 Unlike 
other hydrophobic hormone carrier proteins, VDBP has high 
plasma concentration relative to its major ligand vitamin D3. 
Only less than 5% of VDBP binding sites are occupied by 
vitamin D sterols.30 Besides providing vitamin D bioavail-
ability, VDBP may play a role in innate immunity (neutrophil 
chemotaxis and macrophage activation). Serum VDBP levels 
were lower in patients who developed organ dysfunction and 
sepsis after traumatic injury, and depended on the degree of 
organ dysfunction, respiratory failure, hematologic failure, 
and sepsis. Thus, low VDBP levels could be a significant 
predictor of mortality after injury.31 On the other hand, high 
levels of serum VDBP were associated with decreased lung 
function, expressed in reduced FEV
1
; also, high levels of 
airway VDBP correlated with macrophage activation.32
The structure of each GC polymorphism differs in the 
sugar chain.33 The oligosaccharide structure and its neighbor-
ing structure have been reported to be related with different 
induction of macrophage activating signal.10,33 Given the 
different immunomodulatory roles of VDBP according to 
GC polymorphism, we investigated the relationship of GC 
polymorphisms with COPD clinical characteristics, including 
vitamin D status as a covariate in this study. The results 
show that FEV
1
/FVC, 6MW distance, and emphysema index 
were associated with certain types of VDBP polymorphism. 
Although often considered as a single disease, emphysema 
and COPD overlap less than previously thought, and emphy-
sema on CT shows only moderate correlation with lung 
function.34,35 In a previous study, we could not demonstrate 
the relationship between plasma vitamin D3 level and emphy-
sema severity.6 Here, we evaluated the combined effects of 
GC polymorphisms and vitamin D3 level on emphysema 
in patients with COPD, and found that the GC1S variant 
and genotype 1F-1S were associated with higher emphy-
sema index regardless of vitamin D deficiency. In contrast, 
genotype 1S-1S correlated with lower emphysema index, 
although the association was inconclusive because of a small 
number of genotype 1S-1S patients (N=8). In Japan, patients 
carrying the GC1F variant have been observed to have higher 
frequency of the emphysema index over 60.18 Moreover, a 
recent genome-wide study performed on a large cohort in the 
USA has revealed that certain genes previously identified as 
being related to pulmonary function have been found to be 
independently associated with emphysema rather than with 
pulmonary function.34
To the best of our knowledge, this is the first study to 
determine the combined relationship of COPD with GC 
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polymorphisms and vitamin D deficiency in Korean popu-
lation; however, it had some limitations. First, the sample 
size was small, especially for genotype 1S-1S; the results 
should be interpreted with caution. Given the diversity of 
GC polymorphisms, a larger number of participants are 
required to evaluate the role of each single GC polymor-
phism in COPD. Second, blood levels of VDBP, which is 
the key molecule to clarify the relationship between GC 
polymorphisms and plasma vitamin D3 level, were not mea-
sured. Finally, the information on supplementary vitamin D 
intake was not available. Dietary vitamin D can influence 
the blood level of vitamin D3; so it can affect the analysis 
of the association between GC polymorphism and vitamin 
D3 level in blood.
Conclusion
This study suggests that GC polymorphisms are associated 
with vitamin D deficiency in Korean patients with COPD. 
The GC2 variant was identified as a potential risk fac-
tor for vitamin D deficiency, while genotype 1F-1S was 
determined as a protective factor. Vitamin D deficiency and 
GC polymorphisms were associated with airway obstruction 
and exercise capacity, and GC polymorphisms correlated 
with emphysema severity. The relationship between GC 
polymorphisms and vitamin D deficiency as well as func-
tional differences among GC polymorphisms need to be 
investigated in studies on larger patient cohorts with different 
ethnic backgrounds.
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